MSI2 and lung cancer: In conclusion, MSI2 and RBM17 played a radioresistant role in lung cancer radiotherapy, and RBM17 played a more important role for MSI2 in lung cancer radioresistance, which is consistent with the mechanism that MSI2 promotes radioresistance by activating ATR through the assistance of RBM17 into the nucleus.